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11. Introduction
1.1 Tissue engineering
Each year, millions of people suffer from tissue loss or end-stage organ failure by cancer,
congenital anomaly, or trauma that could be treated with artificial organs (including tissues)
or organ transplantation that are the first choice to reconstruct the devastated tissues or organs
[1]. Although those therapies have much advanced, many patients die while waiting for the
transplantation of tissues or organs due to the limitations in suitable donor tissues [2, 3]. After
transplantation of xenogenic or allogenic tissue patients might have to accept a life-long
immunosuppressive therapy with its associated effects such as renal failure, liver toxicity,
hypertension, and diabetes mellitus for organ transplantation and also are at risk of infection,
acute and chronic rejection [4].
Tissue engineering as a new potential treatment provides solutions to many kinds of disease.
In 1993, the term tissue engineering was described by Langer and Vacanti as “an
interdisciplinary field that applies the principles of engineering and life sciences towards the
development of biological substitutes that restore, maintain, or improve tissue function”[5]. In
2005, MacArthur and Oreffo defined tissue engineering as the “understanding the principles
of tissue growth, and applying this to produce functional replacement tissue for clinical
use”[6].
Tissue engineering can be used to enhance tissues and organs functions. In general, there are
three main approaches in tissue engineering and regenerative medicine: (i) to use freshly
isolated or cultured cells for cellular therapy; (ii) to use biomaterials for tissue regeneration in
2situ; and (iii) to use a combination of cells and scaffolds [7] (Figure 1.1) according to the
definition of tissue engineering as described above. The major goal of tissue engineering is to
replace or to repair damaged tissues or organs and to achieve complete tissue regeneration. In
order to create bioartificial tissues, three main components are combined as described in
figure 1: cells, matrices, and growth factors [8].
Figure 1.1 General strategies for tissue engineering: harvested cells, bioactive factors,
scaffold.
The cells are the elements for functional tissues and thus play a significant role in tissue
engineering. There are two main types of cells that can be used for tissue engineering [9]. One
option would be to use mature autologous organ-specific cells from the patient itself.
Nevertheless, it is a problem that mature cells are difficult to harvest in a sufficient number
and in an adequate quality of cells, especially in the case of older patients. For example, it is
exceedingly hard to harvest cardiac cells and spinal cord or peripheral nerve cells from
patients [1]. The other type of cells which can be harvested from patients, stem cells, might
3solve this problem. Adult stem cells such as mesenchymal stem cells for instance are more
proliferative and have a higher differentiation potential .
Scaffolds consisting of different types of biomaterials are designed to give a certain shape to
the bioengineered tissue and to guarantee the mechanical properties. In addition, they serve as
carriers for implanted cells or delivery systems for growth factors involved in tissue
regeneration. As such they are also important subjects for tissue engineering and regenerative
medicine. Multiple types of scaffolds have been developed for tissue engineering, but the aim
of a clinically useful tissue scaffold is still problematic. A good scaffolding material for tissue
engineering should be stable, biocompatible and should support the tissue regeneration at site
of implantation [11]. The interaction of the material with the tissue and specific cell types is
an important criterion to select the biomaterial but also includes a suitable scaffold shape.
Scaffolds should be designed to perform some biological functions. Firstly, scaffold should
promote cell adhesion and spreading of cultured cells on the artificial extracellular matrix
which can be supported by including sequences derived from elastin and fibronectin [12]. In
the second place, scaffolds should allow sufficient transport of O2, CO2, nutrients, and
regulatory factors to support cell proliferation and differentiation [13]. This can be guaranteed
by the physio-chemical properties and the scaffolding architecture including factors such as
pore size and interconnectivity. Finally, scaffolds would have to keep a balance between
biodegradation resulting in products causing no inflammation or toxicity [14, 15] and the rate
of tissue regeneration. In the future, the biomaterials should be useful to control cellular
signaling processes and cell-matrix interactions involved in tissue repair.
There are so many proteins that play an important role in proliferation and differentiation of
cells during tissue repair and which be used in tissue engineering and regenerative medicine.
These proteins, such as bone morphogenetic proteins (BMPs), basic fibroblast growth factor
(bFGF or FGF-2), vascular endothelial growth factor (VEGF), and transforming growth
factors-β (TGF-β), are secreted by cells themselves or as a result of communication with
surrounding cells [16]. These proteins are called cell growth factors that start their biological
4action by binding to specific receptors on the surface of target cells. Understanding the
biological functions and performances of extracellular matrix proteins and growth factors is
necessary for the strategic delivery of growth factors. This is due to the fact that extracellular
matrix contains many components such as adhesive molecules, and proteins regulating the
activity of a number of growth factors [17]. Thus, it is essential to know how to deliver
growth factors to the site of action. Three methods have been used for the growth factor
delivery [1]: (1) DNA plasmids that include the gene encoding for the desired growth factors.
(2) Genetic modified cells secreting growth factors at implantation side. (3) Growth factor
protein added to a carrier in the sense of drug delivery. The science and engineering behind
growth factor delivery providing a high impact on regenerative medicine will progress in the
future.
1.2 Bone tissue engineering
Bone is a dynamic, highly vascularised and innervated tissue, subjected to continuous healing
and remodeling without leaving a scar [18]. Fracture healing is the result of bone regeneration
through intramembranous and/or endochondral ossification and the healing process results in
the new formed bone which is not different from the adjacent healthy bone [19]. However,
bone regeneration fails in some cases because there are so many risk factors such as gender,
age, diet, diabetes, smoking, alcohol, type of fracture and infection in fracture healing [20].
Considering the growing number of patients who suffer from large bone defects occurring
after trauma, infection, tumor resection, it is critical for scientists and doctors to enhance the
bone healing process [21].
1.2.1 Scaffolds for bone tissue engineering
Bone defects and injuries represent a common clinical problem in our society. Most therapies
5in the clinical practice are based on autografts for bone defects [22]. The current gold standard
for bone transplantation are autografts including all the three elements for new bone growth:
osteoconductivity, osteogenicity, and osteoinductivity [23]. However, autografts have
numerous drawbacks that can induce additional surgical procedures, post-operative pain,
blood loss, hematoma formation, nerve injury, infection and cosmetic defects [24].
Considering the complications associated with bone graftings, suitable scaffolds can support
the bone repair by guiding the proliferation and differentiation of cells and acting as
mechanical stabilizer.
Several scaffolds are available and they may be classified as natural or synthetic biomaterials
that are to provide a 3D environment for cells and tissue to grow on. Natural polymers usually
have organized structures which induce cellular growth at various stages of development [25].
Biodegradable polyurethane (PU) is a very useful biocompatible material that has been used
as a temporary extracellular matrix for bone tissue engineering, but biocompatible
polyurethane is lacking of bioactive groups and thus has limitations in osteoinductivity and
osteoconductivity [26]. It is possible that polyurethane coated with bioactive ceramic particles
such as hydroxyapatite would enhance the bioactivity and improve the mechanical properties
of the scaffold for bone tissue engineering [27] (Figure 1.2).
6Figure 1.2 Photo of PU-HA scaffold [28].
Hydroxyapatite (HA) is the major inorganic component of natural bone and has been made
from calcium phosphate for the use as an orthopaedic and dental material because of its
excellent bioactive and biocompatibility properties [29]. HA is an important component of
medical relevance in terms of its strong osteoconductive but minimally osteogenic properties
[30]. The synthesis of HA powder has been performed over the past years using different
techniques, such as precipitation, hydrothermal, and sol-gel methods [31]. The commonly
used scaffold architectures reported in the literature for proper cellular seeding and
vascularization is a pore size of at least 100 μm [32]. The inclusion of HA into the PU will
improve the mechanical properties as well as the cell differentiation and proliferation for bone
regeneration. Many advantages for this type of scaffold derive as well from the economical
effective and technically simple production procedure which will have an impact on bone
tissue engineering in the future.
1.2.2 Bone tissue engineering with mesenchymal stem cells
Bone marrow contains mesenchymal stem cells (MSC) which are a widely used cell type for
bone tissue engineering strategies as described in the scientific and clinical literature (Figure
1.3). MSC support hematopoietic stem cells and are able to differentiate into multiple cell
lineages, including bone, cartilage, muscle, marrow stoma, tendon, fat, dermis, and
connective tissues [33] (Figure 1.4). In 1970, bone marrow stromal cells were reported by
Friedenstein and colleagues who demonstrated that stromal cells can be described as
colony-forming unit-fibroblasts (CFU-f) . Actually, MSC are isolated from low-density
mononuclear fraction, and resemble 0.001-0.01%, of the total population in bone marrow. By
their adherence to plastic surfaces the can be distinguished from hematopoietic cells [35, 36].
It is considered to be easy and effective to isolate and to expande MSC as well as to
differentiate them into multiple lineages under specific culture conditions. They can be
7isolated from various kinds of biological sources such as bone marrow, peripheral blood,
umbilical cord blood, and placenta [37]. Considering the ability of MSC to form osteoblasts,
MSC are very important for enhancing bone regeneration, and thus seem to be of great
potential for bone tissue engineering.
Figure 1.3 Overview of morphology of mesenchymal stem cell.
In bone repair and regenerative medicine, it has been shown that it is possible to use MSC for
clinical applications because they are not only to harvest easily and in high cell numbers, but
also easily to culture and keep their differentiation potential for bone tissue engineering [38].
Furthermore, MSC can be differentiated very effectively into osteoblastic cells, compared to
their lower potential to develop chondrocytes or adipose cells [39]. The differentiation of
MSC into osteoblastic phenotype was achieved by osteogenic supplements dexamethasone,
beta-glycerolphosphate, and L-ascorbic acid added to the cell culture medium.
8Figure 1.4 Overview of mesenchymal stem cell differentiation [41].
In some clinical case reports, ex vivo expanded autologous MSC were successfully injected
into large bone defects of patients to treat constricted fracture healing [42]. In addition, it has
been shown that autologous bone marrow mononuclear cells implanted in the necrotic lesion
of the femoral head result in the effective treatment of early stages of osteonecrosis [43].
When MSC proliferate and differentiate into osteogenic lineages, different growth factors are
released from their neighbor cells during the formation of new bone [44, 45]. Further, MSC
are also able to assist the neovascularization process by releasing of proangiogenic factors
containing vascular endothelial growth factor (VEGF), angiopoetin-1 (Ang-1) and basic
fibroblast growth factor (bFGF) [46]. In summary, MSC are a promising candidate cell type
for the generation of new bone and might be also supportive in the formation of new blood
vessels.
91.2.3 Bone blood vessel in bone regeneration
The development of a functional vascular system is a prerequisite for successful fracture
healing and is therefore a highly important task in bone tissue engineering. Therefore the
mechanism of neovascularization have to be understood in order to create new therapeutical
tools to support this regeneration process. During embryonic development mesoderm derived
precursor cells such as hemangioblasts are stimulated by VEGF and FGF signaling to undergo
their first critical steps of differentiation to both hematopoietic and endothelial cells (EC) [47]
(figure 1.5). The sufficient production of blood cells is supported by hematopoietic stem cells
in bone marrow. In the early embryogenesis, a primary capillary network develops by a
process called vasculogenesis in which angioblasts, or endothelial progenitors, differentiate to
form primitive blood vessels. VEGF and its the signaling through VEGF-R2/FIK-1, plays an
important role in this developmental process [48] (figure 1.5).
In contrast to these processes in the development, it was thought that the blood vessel
formation in an adult organism is purely based on the sprouting or splitting of existing
capillaries. This process defined as angiogenesis is dependent on the dominant proangiogenic
action of VEGF and angiopoietin 2 (figure 1.5). Subsequently, the vessel stabilization is the
related to the recruitment of pericytes and smooth muscle cells to support a mature
vasculature.
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Figure 1.5 Overview of vascular development [49].
Bone is one of a well-vascularized tissues in the body. The periosteum, the surrounding
muscles and the outer 1/3-rd of the underlying cortex are supplied by the periosteal circulation
and the medullary circulation supplies the inner 2/3-rds of the cortex and bone marrow [50].
The bone vasculature consists of an arteriole, which divides into a complex anastomosed
network of capillaries [15]. The vascular network supplies nutrients for mesenchymal cells
which differentiate into chondrocytes followed up by endochondrial bone formation in a
secondary ossification centre [51]. Thus, the development of vessel network is essential to the
homeostasis of bone tissue.
It is a common conception that atrophic non-unions are usually more difficult to treat, as they
suffer from poor blood supply at the fracture site [52]. Thus, the concept has been developed
that enhancing vascularization in the field of non-union fracture is essential for advancing the
orthopedic care. This concept is also supported by new findings regarding the types of
mechanisms involved in new blood vessel formation, which identified the contribution of
hemangioblasts or endothelial progenitor cells in adult blood vessel formation and repair. In
1997, endothelial progenitor cells were initially identified by Isner and Asahara who
demonstrated that progenitor cells were able to initiate neovascularization in vitro and vivo
[53]. Since then endothelial progenitor cells are thought to make a significant contribution to
vessel growth, both in the embryo and in ischemic, malignant or inflamed tissue in the adult
[54]. Adult vasculogenesis occurs through differentiation of local endothelial progenitor cells,
or more likely, through circulating endothelial progenitor cells (EPCs) [55] recruited to the
sites of blood vessel reorganization. Endothelial progenitor cells are suggested to release
angiogenic growth factors that promote blood-vessel development [56]. Nevertheless, until
now no consensus on the definition of endothelial progenitor cells and their method of action
exists. Therefore, it is important that isolation methods, the identification of EPC, as well as
the knowledge about their methods of action further develops in order to apply such cells for
the bone vascularization and regeneration.
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According to the literature , there are two main a populations of cells which can be isolated
from the mononuclear cell fraction from the peripheral blood which are defined as early
endothelial progenitor cells and colony forming endothelial cells or outgrowth endothelial cell
according their time-dependent appearance [57] (figure 1.6). These cells types develop from
mixed populations of mononuclear cells which are cultured in an endothelial cell culture
medium with endothelial growth factors on collagen or fibronectin coated cell culture plates.
After several days, the adherent cells with spindle shaped morphology express cell surface
markers such as CD34, CD31 and CD45 [58]. Those cells which show some endothelial
markers but also hematopoietic characteristics such as the expression of CD45 are termed
early endothelial progenitor cells. In contrast, late EPC, named also outgrowth endothelial
cells (OEC) or endothelial colony forming cells appear as endothelial colonies after 3 weeks
in culture. These cells are considered as mature endothelial cells according to their endothelial
phenotype and their high proliferative, migratory, and tube forming capabilities [59]. OEC
exhibit a typical cobblestone-like morphology [60] and show key characteristics of mature
endothelial cells such as the expression of CD31, CD34, and CD146 [58]. Despite differences
of EPC and OEC in gene expression, they both have been shown to contribute to
neovasculogenesis in vivo. It has been shown that early EPC secrete angiogenic cytokines
which trigger angiogenesis, whereas OEC act as mature endothelial cells and are able to
provide a sufficient number of endothelial cells [57].
EPC OEC
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EPC OEC
Spindle shaped morphology Cobblestone-like morphology
After 7 days in culture After 2-3 weeks in culture
CD31+, vWF (+) CD31+, vWF (+++)
CD45+, CD14+, CD146- CD45-, CD14-, CD146+
Low proliferative potential High proliferative potential
No tube formation Tube formation
Secretion of angiogenic factors High vasculogenic potential
Figure 1.6 Overview of morphology of endothelial progenitor cells and outgrowth endothelial
cells [56, 57, 59-62].
Signaling processes by angiogenic growth factors make a significant contribution to new
blood vessel formation in the bone. In this context also VEGF plays a critical role in
angiogenesis. Studies by Asahara have demonstrated that vascular endothelial growth factors
(VEGF) is not only essential for increasing endothelial cell differentiation and proliferation,
but also enhances tube formation and the mobilization as well as the recruitment of
endothelial progenitor cells [63]. VEGF is highly increased in the early phases post-fracture
and has been shown to promote the bone formation during distraction osteogenesis in fracture
healing [64]. This important role for VEGF signaling in bone repair is supported for instance
by studies using VEGF receptor-1 and VEGF receptor-2 blocking antibodies [65].
Hypoxia-inducible factor (HIF) pathway plays a central role in activating angiogenesis in
areas of low oxygen tension, including the avascular portion of the cartilaginous callus [66].
As such VEGF gene expression is enhanced directly by the transcription factor HIF. Lastly, it
is well-accepted that signaling molecules play a role in vascularization at the fracture site.
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1.3 Myeloid cells and macrophage-like cells in vascularization
Hematopoietic stem cells are multipotential cells residing in the bone marrow which give rise
to all blood cell types including myeloid (monocyte, macrophage, neutrophil, eosinophil,
basophil, megakaryocyte, platelets, and red blood cells) and lymphoid (B cells, T cells, and
natural killer cells) cell lineages [67] (figure 1.7).
Figure 1.7 Hematopoietic stem cells give rise to myeloid progenitor cell lineages and
lymphoid progenitor cell lineages [68].
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Cells of monocytic lineages are related to circulating blood progenitors with partly
macrophage-like characteristics which are involved in the repair and neovascularization in a
series of different tissues [69]. Myeloid angiogenic cells and endothelial progenitor cells share
a series of common characteristics in terms of the secretion of proangiogenic molecules and
the active contribution to blood vessel reorganization. For instance myeloid cell derived
interleukin-8 (IL-8) is able to transactivate vascular endothelial growth factor receptor-2
(VEGFR2) independently of extracellular VEGF [70]. Myeloid cells are known to improve
angiogenesis in experimental set up [71]. Macrophages belong to the myeloid cell lineages
that arise from monocytic progenitor cells that differentiate into tissue macrophages.
Macrophages have a range of different phenotypes depending on the environmental stimuli
[72]. Activated macrophages include classical activated M1 phenotypes, associated with
active microbial killing and proinflammatory characteristics, and alternative activated M2
phenotypes, associated with tissue remodeling and proangiogenic function [71] (figure 1.8).
M2 are supposed to play a key role in angiogenesis by releasing a number of potent
proangiogenic growth factors such as VEGF and bFGF [73]. Accordingly, myeloid cells and
macrophage cells have major therapeutic value in the clinical setting.
15
Figure 1.8 Macrophages with distinct phenotypes [74].
1.4 Co-culture system in bone tissue engineering
Bone regenerative medicine in general as well as the still unsolved problem of the
neovascularization in larger bone defects remains a significant clinical challenge. Co-culture
models were used for analysis of cell-to-cell communication through three mechanisms: (i)
direct membrane-membrane interactions between two adjacent cells, (ii) adjacent cells
communicating using gap junctions form direct connectivity between two cytoplasms, and (iii)
factors released from extracellular matrix that activate receptors on the target cells [75]. In
this context co-culture approaches have been established due to the findings by several groups
aiming at the prevascularization of tissue engineered constructs. The vasculature is essential
for oxygen delivery, nutrients exchange, and soluble factors transport to support new bone
formation in the body [76]. In co-culture models, VEGF secreted by bone-forming cells
containing mesenchymal stem cells, osteoprogenitors, and osteoblasts plays a major role in
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osteo-endothelial communication [77, 78]. On the other hand, VEGF also can support the
recruitment of progenitor cells and lead to their differentiation into osteoblasts through
activation of receptors [79]. In addition, it is well-accepted that osteoblasts seem to be a
considerable cellular source of angiopoietin-1 (Ang-1) [80] and that VEGF and Ang-1
promote angiogenic response and vascular stabilization [81]. The cellular crosstalk
phenomena in co-culture models guiding angiogenesis and osteogenesis during bone repair
show a high degree of complexity [82], but this knowledge is essential for the translation of
bone tissue engineering. In addition to use these models as tools to study bone repair
processes co-culture approaches or co-implantations strategies seem to be a therapeutical
option to enhance bone and vascularization.
1.5 Aim of the study
The development in science and in new technologies, has resulted in clear improvements in
the field of vascularized bone tissue, but large bone defects/injuries still represent a major
challenge in the field of bone tissue engineering and regenerative medicine. An understanding
of the interaction of osteogenesis and angiogenesis will enhance the process of bone
development and repair. In vivo, EPC have proved their therapeutic potential ability to form
vascular networks that will allow suitable vascularization of engineered organs and tissues
[83]. Endothelial progenitor cells isolated from human peripheral blood seem to be a potential
autologous cell source for neovascularization in bone tissue engineering. The present study is
focused on the role of endothelial progenitor cells in the formation of angiogenic structures in
different co-culture models. Using this co-culture model to mimick the bone regeneration
process the effect of EPC on angiogenic structures was evaluated. According to present
knowledge endothelial progenitor cells might act myeloid cells, Therefore endothelial
progenitor cells were added to co-cultures of MSC and OEC and their properties to support
new blood vessel formation were investigated in vitro. The co-localization of myeloid cells
and angiogenic structures are analyzed by CLSM, and the formation of angiogenic structures
17
were analysed quantitatively in the vitro model system. Analysis of the molecular
mechanisms in the angiogenic process and angiogenic activation including vascular growth
factors and factors involved in vessel stabilization was performed to understand the
interaction of different cell types. This also included the evaluation of myeloid marker to
assess a potential contribution of myeloid cells contained within the EPC cultures.
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2. Materials and Methods
2.1 Materials
2.1.1 Instruments
Instrument Model Manufacturer
Centrifuge Biofuge primo R Thermo Scientific, Langenselbold,
Germany
Centrifuge Multifuge 3 S-R Thermo Scientific, Langenselbold,
Germany
Cyro-microtome HM550 Thermo scientific, Dreieich, Germany
Analytical balance BP211 D Sartorius, Göttingen, Germany
Fluorescence
microscope
Axioskop 40 Zeiss, Germany
Fluorescence
microplate reader
Spectra fluor plus Tecan, Crailsheim, Germany
Fridge (4 °C) Uks 3602 index
12/001
Liebherr, Austria
Freezer (-20 °C) Premium no frost Liebherr, Austria
Freezer (-80 °C) Hera freeze Heraeus, Hanau, Germany
FUSION imaging
system
Fusion SL vilber
lourmat
PEQLAB, Erlangen, Germany
Incubator Hera cell 240 Heraeus, Hanau, Germany
Laminar flow Hera safe Heraeus, Hanau, Germany
Light microscope Axiovert 25 Zeiss, Göttingen, Germany
Liquid nitrogen tank Locator 4 plus Thermo Scientific, Dreieich, Germany
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Micro plate reader Apollo LB 911
TECAN
Berthold Technologies, Austria
Nano Drop Nano Drop 2000 Peqlab, Erlangen, Germany
Orbital Incubator SI50 Stuart, ST15 OSA, UK
pH meter HI 991001 HANNA, Kehl am Rhein, Germany
Pipette 10 µl, 100 µl, 1000µl Eppendorf, Hamburg, Germany
Pipetus 100-240 volt Hirschmann Laborgeräte, Eberstadt
Germany
Real Time PCR cycler iCycler iQ Bio-Rad, Hercules, CA, USA
Vacuum pump Vacu boy Integra Biosciences, Fernwald, Germany
Vortex Vortex-Genie2™ Scientific Industries, New York, USA
2.1.2 Consumables
Consumable Manufacturer
Cell strainer (40 µm, 100 µm) BD Falcon, Franklin Lakes, NJ, USA
Centrifuge tubes (15 ml, 50 ml) Sarstedt, Nümbrecht, Germany
Cover glasses (18x18 mm) Menzel-Gläser, Braunschweig, Germany
Cryovials (2 ml, 5 ml) Greiner, Frickenhausen, Germany
ELISAMicroplate (96 well) Nunc, Langenselbold, Germany
Lab-Tek Chamber slide (2 well, 8 well) Nunc, Langenselbold, Germany
Laboratory bottle (100 ml, 250 ml, 500 ml, 1 l) Schott, Mainz, Germany
Microscope slides Menzel-Gläser, Braunschweig, Germany
Micro tubes (1,5 ml, 2 ml) Sarstedt, Nümbrecht, Germany
Parafilm Pechiney Plastic Packaging, Menasha, USA
Pasteur pipettes Hecht-Assistant, Sondheim, Germany
Pipette tips (10 µl, 100 µl, 1000 µl) Greiner, Frickenhausen, Germany
Pipette tips (1000 µl) Sarsted, Nümbrecht, Germany
Pipette filter tips (10 µl, 100 µl, 1000 µl) Sarstedt, Nümbrecht, Germany
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Ritip (1,25 ml, 2,5 ml, 5 ml, 12,5 ml) Th. Geyer, Hamburg, Germany
Save seal micro tubes (0,5 ml) Sarstedt, Nümbrecht, Germany
Serological pipettes (5 ml, 10 ml, 25 ml) Sarstedt, Nümbrecht, Germany
Tissue culture flasks (25 cm², 75 cm²) Sarstedt, Nümbrecht, Germany
Tissue culture plate, 24-well TPP, Trasadingen, Switzerland
Tissue culture plate, 96-well Sarstedt, Nümbrecht, Germany
2.1.3 Chemicals
Name Manufacturer
β-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany
β-glycerol phosphate Sigma, St. Louis, MO, USA
Ascorbate-2-phosphate Sigma, St. Louis, MO, USA
Biocoll Separating Solution Biochrome, Berlin, Germany
BSA (albumin from bovine serum) Sigma, Steinheim, Germany
Collagen Type I Rat Tail (3,66 mg/ml) BD Biosciences, Bedford, MA
DAPI (4’,6-diamidino-2-phenylindole) Molecular Probes, Eugene, Oregon,
USA
Dexamethasone Sigma, St. Louis, MO, USA
DMEM, high Glucose (4,5 g/l) PAALaboratories, Pasching, Austria
DMEM/Ham’s F-12 (1:1), with stabile glutamine Biochrom, Berlin, Germany
DMSO (dimethyl sulfoxide) Sigma-Aldrich, Steinheim, Germany
EGM-2 BulletKit® (endothelial growth medium 2) Lonza Walkersville, MD, USA
Elite mouse IgG Vectastain, Germany
Fluoromount Sigma, St. Louis, MO, USA
FBS (fetal bovine serum) PAALaboratories, Pasching, Austria
Fibronectin (human plasma fibronectin purified
protein) (1 mg/ml)
Millipore, Temecula, CA, USA
Freezing medium Leica, Germany
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Impact DAB Vectastain, Germany
Paraformaldehyde (4 %) USB, Cleeveland, USA
Penicillin/Streptomycin (100x) (10.000 U/ml/10
mg/ml)
PAALaboratories, Pasching, Austria
PBS Dulbeco’s (1x) (phosphate-buffered saline) PAALaboratories, Pasching, Austria
PBS Dulbeco’s (10x) (phosphate-buffered saline) PAALaboratories, Pasching, Austria
QuantiTectTMSYBR®Green PCR Master Mix Qiagen, Hilden, Germany
QuantiTectTM SYBR® Green primer assay Qiagen, Hilden, Germany
RNase free water Qiagen, Hilden, Germany
Substrate Reagent Pack R&D Systems, Wiesbaden, Germany
Triton™ X-100 Sigma, Taufkirchen, Germany
Trypsin/EDTA (10x) PAALaboratories, Pasching, Austria
Tween® 20 Roth, Germany
2.1.4 Antibodies
Primary antibody Source Dilution Manufacturer
anti-human CD31 mouse 1:50 Dako, Glostrup, Denmark
anti-human CD11b rabbit 1:50 Epitomics, Burlingame, CA, USA
Secondary antibody Source Dilution Manufacturer
Alexa Fluor 488 anti
mouse
goat 1:1000 Invitrogen-Molecular Probes, Eugene,
Oregon, USA
Alexa Fluor 555 anti
rabbit
donkey 1:1000 Invitrogen-Molecular Probes, Eugene,
Oregon, USA
2.1.5 Primers
Gene name Primer assay name Catalogue number
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vWF Hs_VWF_1_SG QuantiTect Primer Assay Quiagen/QT00051975
CD146 Hs_MCAM_1_SG QuantiTect Primer Assay Quiagen/QT00079842
sm-Actin Hs_ACTA _1_SG QuantiTect Primer Assay Quiagen/QT00088102
CD11b Hs_ITGAM_1_SG QuantiTect Primer Assay Quiagen/QT00031500
IL-8 Hs_IL8_1_SG QuantiTect Primer Assay Quiagen/QT00000322
CD68 Hs_CD68_1_SG QuantiTect Primer Assay Quiagen/QT00037184
CD163 Hs_CD163_1_SG QuantiTect Primer Assay Quiagen/QT00074641
Integrin α5 Hs_ITGA5_1_SG QuantiTect Primer Assay Quiagen/QT00080871
GAPDH Hs_GAPDH_1_SG QuantiTect Primer Assay Quiagen/QT00079247
Gene name Sequence Annealing temperature
CD 31
For 5’-
CCGGATCTATGACTCAGGGACCAT-3’
rev 5’-GGATGGCCTCTTTCTTGTCCAG-3’
(Eurofins)
55°C
VEGF
for 5’-AAATGTGACAAGCCAAGGCGG-3’
rev
5’-AAAGTGCTCCTCGAAGAGTCTCC-3’
(Eurofins)
55°C
2.1.6 Kits
Name Manufacturer
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DuoSet® human CXCL8/IL-8 R&D Systems, Wiesbaden, Germany
DuoSet® human VEGF R&D Systems, Wiesbaden, Germany
Quant-iT Pico Green dsDNAAssay Kit Invitrogen, Germany
RNeasy Micro kit Qiagen, Hilden, Germany
RNeasy Kit Qiagen, Hilden, Germany
RNA-to cDNAKit Applied Biosystems, Carlsbad, USA
2.2 Isolation and expansion of human endothelial progenitor cells
(EPC) and outgrowth endothelial cells (OEC)
Endothelial progenitor cells and outgrowth endothelial cells were isolated and cultured
according to protocols as described previously . The mononuclear cells were isolated from
peripheral blood buffy coats, 25ml peripheral blood was diluted 1:2 with 25ml phosphate
buffered saline in 50ml tube and then 35ml of this mixture that was carefully added to 15 ml
of Bicoll were centrifugated for 35 minutes at 400 x g without break, by Biocoll gradient
centrifugation (figure 2.1). The mononuclear cells were cultured in endothelial cell growth
medium-2 (EGM-2) with full supplements from the kit (10 ml FBS, 0.2 ml Hydrocortisone, 2
ml hFGF, 0.5 ml VEGF, 0.5 ml IFG-1, 0.5 ml ascorbic acid, 0.5 ml hEGF, 0.5 ml Heparin),
5% FBS, and 1% penicillin/streptomycin, on collagen coated well plates. 5×106 mononuclear
cells/well were seeded on 24 culture-well plates and then fed with fresh medium every second
day. After 1 week of culture, adherent cells were collected by trypsinization and used as EPC
or reseeded in a density of 0.5x106 cells/well to collect OEC. Then colonies of OEC with
cobble-stone-like morphology appearing after 2-3 weeks in culture were trypsinized and
expanded over several passages as described before.
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Figure 2.1 Isolation of mononuclear cells from peripheral blood buffy coat. According
http://pluriselect.com/buffy-coat.html
2.3 Isolation and expansion of mesenchymal stem cells (MSC)
Human MSC isolated from bone marrow of human cancellous bone fragments of adult donors
were cultured and expanded as previously described [87]. Bone fragments were washed
several times with phosphate buffered saline to collect the loosely associated cell fractions.
The washing solution containing bone marrow residues was filtered by cell strainer and
centrifuged for 10 minutes at 400 x g, and the cell pellet was resuspended in DMEM/Ham
F-12 supplemented with 20% FBS and 1% Penicillin/Streptomycin. Cells were seeded at a
density of 2×106 cells/cm2 on collagen-coated flasks (T75). MSC-like colonies appearing after
7-10 days were expanded using a splitting ratio of 1:3 and were cultivated in DMEM-Ham
F12 supplemented with 20% FBS and 1% Penicillin/Streptomycin. Then MSC were
cultivated in osteogenic differentiation medium (ODM) in passage two for 2 weeks to induce
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osteogenic differentiation before starting experiments. ODM consists of DMEM-Ham F-12
supplemented with 0.1 μM dexamethasone, 10 μM β-glycerol phosphate, 50 mM
ascorbate-2-phosphate, 10%FBS, and 1% Penicillin/Streptomycin.
2.4 Coculture and triple culture of MSC, OEC and EPC
To study the influence of EPC-derived myeloid cells on angiogenesis we used co-cultures
based on 1) MSC and EPC, 2) MSC and OEC and 3) triple cultures of MSC and OEC to
which we added 5% and 10% EPC per total cells. In a first step MSC were seeded onto the
fibronectin coated 24-culture well plates or on fibronectin-coated Thermanox coverslips at a
density of 200.000 cells/well and cultivated in ODM. After 24 h, 200.000 OEC were added
for co-cultures of MSC/OEC, and 200.000 OEC plus 5% or 10% of EPC for triple cultures. In
addition 10% EPC per well were added to MSC for the MSC/EPC set up. Co-culture and
triple-culture were maintained in EGM-2 for 4 or 14 days.
2.5 Immunofluorescence staining
After 4 or 14 days co-cultures and triple-cultures seeded on Thermanox coverslips as
described above were prepared for immunofluorescence staining. After fixation with 4%
paraformaldehyde, cells were washed three times with PBS and permeabilized using 0.1%
Triton®X-100. Cells were incubated with the following primary antibodies diluted in 1%
bovine serum albumin (BSA) in PBS for 1 hour at room temperature: CD31, CD11b. After
washing 3 times with PBS, cells were incubated with the corresponding fluorescently labeled
secondary antibodies diluted 1:1000 in 1% BSA in PBS for 1 hour at room temperature. For
nuclear counterstaining, cells were treated with 4',6-diamidino-2-phenylindole (DAPI).
Samples were then observed using Zeiss LSM 510 Meta confocal laser scanning microscope.
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2.6 Image quantification and colocalization studies
Microscopic images of immunofluorescence-stained co-cultures and triple-cultures at
different time points were analysed using ImageJ 1.43 was preformed by MetaPhysiol, Dr.
Harald Schmidt [88] as introduced previously [89]. In brief, the tube-like structures were
extracted from the immunofluorescent images stained for CD31 [90] and analyzed for the area,
length, branching points and endpoints. According to these results, three regions of interest
were established, the total area of tube-like structures and circular regions (r = 50 pixel)
around the branching- and endpoints. Finally, the immunofluorescent images stained for
CD11b were analyzed for co-localization of positive cells by determination of the integrated
density of CD11b fluorescence at the regions of interest. The relative intensity (relative
intensity = integrated density per area) for each region was calculated and the relative
intensity of the whole image was used as a reference. The results of image analysis
experiments are given as means ± s.d., and significant differences between means were
calculated with MS-Excel. According to the results of a variance ratio analysis (F-test, p<0.05)
an unpaired t-test for either homoscedastic or heteroscedastic variances was performed
(*p<0.05 and ** p<0.01).
2.7 Gene expression analysis
2.7.1 RNA isolation
RNA isolation was performed using RNeasy Micro kit. The medium was taken away from the
24-well-plates, the cells from different experiments were lysed in 500 µl lysis buffer
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containing 1 % -Mercaptoethanol in RLT-buffer to stabilize the lysates. After an incubation
period of 5 minutes, the cell lysates were directly taken into a QIA shredder mini spin column
and centrifugated at 13.000 rpm for 3 minutes. The column was thrown away, 500 µl of 70%
ethanol was added to the cell lysates and mixed till the fluid was clear. Then, maximum 500
µl of the solution was added to the RNeasy Mini away and centrifugated at 10.000 rpm for 30
seconds. After the flow through, the passage was thrown away and this step needed to be
repeated again. To wash the filter, 350 µl RW1 buffer was put into the column and incubated
for 10 minutes. After this, the column was centrifugated at 10.000 rpm for 30 seconds. Then,
78 µl DNase mix (70 µl RDD buffer and 10 µl DNase for one sample) was given into the
column and incubated for at least 30 minutes at room temperature to destroy DNA. After this
incubation time, 350 µl RW1 buffer was added to the column which was centrifugated at
10.000 rpm for 30 seconds. 350 µl of RW1 buffer was given into the column and incubated
for 5 minutes at room temperature for washing the filter, then the column was centrifuged at
10.000 rpm for 30 seconds. The column was transferred into a new 2 ml tube and filtered with
500 µl RPE buffer, before this column was centrifugated at 13.000 rpm for 30 seconds. This
step was repeated again. Therefore, 30 µl of nuclease free water was added to the column and
incubated for 10 minutes. Then the column was centrifuged at 13.000 rpm for 3 min. The
concentration of RNA can be measured by a Nano Drop 2000c spectrophotometer. 2 µl of the
RNA solution was added onto the lower optical surface for measuring. NanoDrop software
was opened to measure the concentration of RNA using a microvolume spectrophotometer.
2.7.2 Reverse transcription
For the transcription of RNA into DNA, 1000 ng RNAwas taken into a solution containing 10
µl RT buffer and 1µl RT Enzyme Mix after the was denatured at 70 o C for 10 minutes. The
solution was filled up to 20 µl with RNAse free water and mixed as well as centrifugated. The
samples were incubated in a water bath at 37 o C for 1 hour. Finally, the solution was
incubated at 95 oC for 5 minutes and filled up to 100 µl with RNAse free water.
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2.7.3 RT-PCR
To assess the expression of endothelial and myeloid markers, as well as the expression of
angiogenic factors, semi-quantitative real-time polymerase chain reaction (RT-PCR) was
performed for CD146, von Willebrand factor (vWF), CD31, sm-actin, CD11b, IL-8, VEGF,
and Glycerin-Aldehyde-3-phosphate (GAPDH) as internal control. For detailed information
of used primers please refer to table 1. For gene expression analysis, total RNA was extracted
from different culture set ups using RNeasy Kit according to the manufacturer’s protocol. A
total amount of 1µg RNA was transcribed into cDNA using High capacity RNA-to cDNA Kit.
Quantitative real-time PCR was performed using iCycler iQ Real-Time Detection System.
12.5 µL of QuantiTectTM SYBR® Green PCR Master Mix, 2.5 µL of QuantiTectTM SYBR®
Green primer assay, 6 µL of RNase free water, and 4 µL of cDNA were used for one reaction.
For amplification, the following thermocycler program was performed. 1 cycle: 2 min at 50 o
C; 1 cycle: 8 min at 95 o C; 40 cycles: 30 s at 95 oC, 30 s at 55 o C, 30 s at 72 o C; 80 cycles:
30 s at 55 oC; 1 cycle: hold at 20 oC. Glycerin-Aldehyde-3-phosphate (GAPDH) was used as
internal control and relative gene expression was determined using the ΔΔCt method. Gene
expression was compared setting control cultures to 1 (reference value) as indicated in the
relevant figures.
2.8 Quantification of different growth factors using enzyme-linked
immunosorbent assay (ELISA)
The concentration of different growth factors in cell culture supernatants from different
culture set ups of MSC, OEC and EPC in EGM-2 collected after 4 and 14 days were
measured using ELISA DuoSet® for IL-8 and VEGF. ELISA was performed according to the
manufacturer’s instructions. Results for each sample were normalized to the DNA content of
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each sample to compensate for the different cell numbers in the set up
2.8.1 VEGF (ELISA)
Cell culture supernatants were centrifuged and stored at ≤ -20° C. VEGF standard was
prepared with 2000 pg/mL of calibrator diluent RD5K (figure 2.2). 500 µL of calibrator
diluent RD5K was added into each tube and mixed each tube thoroughly before the next
transfer. 50 µL of Assay Diluent RD1W was added to each well. Then 200 µL of standard,
control, or sample were added to each well. The plate was covered with the adhesive strip and
incubated for 2 hours at room temperature. Each well were washed three times with wash
buffer (400 µL) per well. 200 µL of VEGF conjugate was added to each well and incubated
for 2 hours at room temperature. Each well were washed three times with wash buffer (400
µL) per well. 200 µL of substrate solution was added to each well and protected it from light
as well as incubated for 20 minutes at room temperature. 50 µL of stop solution was added to
each well. The optical density of each well was determined within 30 minutes. A
streptavidin-HRP (horseradish-peroxidase) colorimetric reaction was used to determine
protein concentrations. The optical density of each well was measured using an automatic
plate reader capable of measuring absorbance at 450 nm. After background subtraction
concentrations were determined according to a standard calibration curve.
Figure 2.2 Prepare VEGF standard. According R&D systems.
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2.8.2 IL-8 (ELISA)
The 96-well microplate were coated with 100 µL per well of the diluted Capture Antibody and
incubated overnight at room temperature. Each well were washed three times with wash
buffer (400 µL) per well. The plate was blocked by adding 300 µL of Block Buffer to each
well and incubated at room temperature for a minimum of 1 hour. Each well were washed
three times with wash buffer (400 µL) per well. 100 µL of standard or sample was added to
each well and covered with an adhesive strip as well as incubate for 2 hours at room
temperature. Each well were washed three times with wash buffer (400 µL) per well. 100 µL
of the detection antibody diluted in reagent diluent was added to each well and incubated 2
hours at room temperature. Each well were washed three times with wash buffer (400 µL) per
well. 100 µL of the working dilution of Streptavidin-HRP was added to each well and
incubated for 20 minutes at room temperature as well as avoided placing the plate in direct
light. Each well were washed three times with wash buffer (400 µL) per well. 100 µL of
substrate solution was added to each well and incubated for 20 minutes at room temperature
as well as avoided placing the plate in direct light. 50µL of stop solution was added to each
well and mixed them. The optical density of each well was measured using an automatic plate
reader capable of measuring absorbance at 450 nm. After background subtraction
concentrations were determined according to a standard calibration curve.
2.8.3 Quantitative DNA
The DNA content of co-cultures and triple cultures was determined by Quant-iT Pico Green
dsDNAAssay Kit according to the manufacturer’s protocol. Trypsinize the cells with 250 µL
Trysin/EDTA per each well and take the cells into Eppi as well as centrifuge at 14000 rmp for
5 min. Then destroy the cells in an ultrasound bath to release the DNA into the supernant.
Make a range standard:
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Stock-std: 100 µg/mL
Working solution: 2µg/mL (20µL stock solution + 980 µL TE buffer)
Table 1. Protocol for preparing a stand curve.
standard Working solution TE-buffer
1ng/mL 1 µL 1999 µL
10 ng/mL 5 µL 995 µL
100 ng/mL 50 µL 950 µL
1000 ng/mL 500µL 500 µL
Then add 100 µL TE buffer into each well. Picogreen solution is diluted 1:200 and 72 µL is
added to each well. For the quantification, 28 µL of the sample and of the standards are added
to wells in a 96 well plate and incubated for 10 minutes in the dark at room temperature.
The DNA content of co-cultures and triple cultures was analysed with a fluorescence
microplate reader at an excitation/emission wavelength of 485/535 nm. In co-cultures and
triple cultures ELISA data were normalized to the DNA content of each sample to compensate
for the different cell numbers in the set up.
2.9 Protein arrays for angiogenesis- and hematopoiesis-related
proteins
In a first step MSC were seeded onto the fibronectin coated 6-culture well plates at a density
of 2.14 x 105 cells/cm2 for MSC monocultures and 1.07 x 105 cells/cm2 for MSC/OEC
co-cultures and triple-cultures (OEC/MSC/10% EPC) and cultivated in ODM. After 24 h,
OEC in a density of 1.07 x 105 cells/cm2 were added for MSC/OEC co-cultures and for
triple-cultures (OEC/MSC/10% EPC). 10% per total cells of EPC were added to triple
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cultures. After 4 days, cells were lysed in buffers according to the recommendations for the
protein arrays. In addition, proteins were harvested from the corresponding cell culture
supernatants after centrifugation. The total protein concentration in individual samples was
determined by the Bradford assay and measured at 562 nm using an automatic plate reader.
Protein-extracts derived from 3 different donors were subsequently pooled group wise at
equal ratios to assess an average protein profile for each sample group. Proteome ProfilerTM
Human Angiogenesis Array and Proteome ProfilerTM Human Hematopoietic Array were
performed according to the manufacturer’s protocol. Proteins were detected by
chemiluminescence and analyzed quantitatively using FUSION imaging system equipped
with fusion software.
2.9.1 Angiogenesis – related proteins
Cell culture supernatants were centrifuged and stored at ≤ -20° C. Cells were washed with
PBS and added lysis buffer. The lysates were rocked gently at 2-8 °C for 30 minutes.
Quantitation of sample protein concentrations using a total protein assay was recommended.
2.0 mL of array buffer 7 as a block buffer was pipetted into each well of the 4-well multi-dish.
Each membrane was placed in a well of the 4-well multi-dish. 4-well multi-dish was on a
rocking platform shaker for one hour. Each sample was added to 0.5 mL of array buffer 4 and
adjusted to a final volume of 1.5 mL with array buffer 5 as necessary. 15 µL of reconstituted
detection antibody cocktail was added to each sample and incubated at room temperature for
one hour. Array buffer 7 was aspirated from the wells of the 4-Well Multi-dish and samples
were added to the wells as well as incubated overnight at 2-8 °C on a rocking platform shaker.
Membranes were washed with wash buffer three times. Then 2.0 mL of diluted
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Streptavidin-HRP was pipetted into each well and incubated for 30 minutes at room
temperature on a rocking platform shaker. Membranes were washed with wash buffer three
times. 1 mL of Chemi Reagent Mix was pipetted onto each membrane and waited for testing.
2.9.2 Hematopoiesis – related proteins
Hematopoietic panel was divided into two parts (H and C). 2.0 mL of 1x array buffer 8/1 as a
block buffer was pipetted into each well of the 4-well multi-dish. Each membrane was placed
in a well of the 4-well multi-dish and was on a rocking platform shaker for one hour. 0.3 mL
of Array buffer 8 was added to each sample and adjusted to a final volume of 3 mL with array
buffer 1 as necessary. 1x array buffer 8/1 was aspirated from the wells of the 4-well multi-dish
and 1.5 mL of the sample was added to each well as well as incubated overnight at 2-8 °C on
a rocking platform shaker. Membranes were washed with wash buffer three times. For part C
and part H array, 30 µL of reconstituted detection antibody cocktail C and H was diluted to
1.5 mL with 1X Array Buffer 8/1. 1.5 mL of the dilution was pipetted into each well of the
4-well multi-dish and incubated for 2 hours at room temperature on a rocking platform shaker.
Membranes were washed with wash buffer three times. 1 mL of chemi reagent mix were
pipetted onto each membrane and waited for testing.
2.10 Prevascularization of polyurethane-hydroxyapatite (PU-HA)
scaffolds
Before cell seeding scaffolds were placed in 96-well plates and coated with 10 µg/mL
fibronectin in PBS for 1 h at 37 °C. PU-HA were seeded with 1) 350.000 MSC and 350.000
OEC or 2) 350.000 MSC and 350.000 OEC plus 5% of total cells EPC (35.000) 3) 350.000
MSC and 350.000 OEC plus 10% of total cells (70.000) EPC and 4) 700.000 MSC and 10%
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(70.000) EPC per scaffold. After seeding MSC in a first step samples were placed in the
incubator for 4 h before transferring them to a new 24-well plate with 1.5 mL of fresh ODM
medium. After 24 h, OEC and EPC were seeded into the MSC-seeded PU-HA scaffolds and
the scaffolds were incubated at 37 °C for 4 and 14 days. Then samples were prepared a) for
CLSM as described previously or b) For cryosections of scaffolds were performed according
to standard procedures after fixing in ice cold methanol. After embedding in freezing medium
scaffolds were sectioned on a cyro-microtome into sections of 9 or 12 µm in thickness.
Sections were postfixed with 4 % paraformaldehyde and stained by immunofluorescence as
described in earlier sections (section 2.5) or by immunohistochemistry using CD31 as primary
antibody followed by the dectection using the elite kit and DAB for the colorometric reaction.
Nuclear counterstaining was performed by hemalaun.
2.11 Statistical analyses
Data are presented as mean values ± standard deviation of the mean. Statistical significance
was assessed using the unpaired students t-test (p-value *p<0.05 and **p<0.01). This test was
chosen to compare different set ups of co-cultures and triple-cultures. Statistical analysis was
performed with Excel. Statistical significance was demonstrated when the p-values were less
than 0.05.
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3. Results
3.1 Colocalization of endogenous CD11b-positive cells in
triple-cultures system
Immunofluorescent labeling of CD11b-positive cells was performed in triple-cultures of MSC
with OEC and EPC after 14 days by CLSM (figure 3.1). In addition, vascular structures have
been visualized by staining for the endothelial marker CD31 (depicted in green) and indicated
the co-localization of CD11b-positive cells (depicted in red) and vascular structures. The
CD11b-positive cells were located near to the vascular structures as indicated by CLSM.
Additional results from the group and corresponding image analysis (not part of the present
thesis) also conformed this morphological observation in statistical evaluations.
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Figure 3.1 Co-localization of myeloid cells with angiogenic structures in triple-cultures
(MSC+OEC+5%EPC) after 14 days. The triple-cultures are stained for CD31 (green) and
CD11b (red), bar=100µm.
3.2 Effects of myeloid cells on angiogenic structures determined by
confocal microscopy and quantitative picture analysis
To further define the role of the CD11b-positive or myeloid cells during angiogenesis and to
see whether EPC act as a source of CD11b-positive or myeloid cells, we actively added early
EPC to the co-culture system and evaluated their effects on the formation of vascular
37
structures.
The formation of angiogenic structures and the associated myeloid cells after 4 (figure 3.2 A,
B) and 14 days (figure 3.2 C, D) were investigated by immunofluoresecent staining for
endothelial markers such as CD31 (A, C; depicted in green). In addition, CD11b (depicted in
red, figure 3.2 A-D) was used as a marker for myeloid cells. During the time course of the
co-cultures OEC formed angiogenic structures characterized by elongated endothelial
morphology. The addition of early EPC to the co-cultures of MSC and OEC seemed to
increase the number of vascular structures present in the co-cultures, whereas in additional
controls of MSC/EPC co-cultures no vascular structures were detected at the investigated time
points. Myeloid cells were characterized by a more rounded morphology and CD11b
expression depicted in red. In addition, rounded CD11b-positive cells partly expressed also
the endothelial marker CD31. CD11b-positive myeloid cells were closely associated with the
angiogenic structures, indicating an active role in the formation of vascular structures to be
further defined. A potential integration of myeloid cells into vascular structures might occur
but could not be proven at the present stage of investigation.
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Figure 3.2 Immunofluorescent staining of co-cultures (MSC+10%EPC, MSC+OEC) or
triple-cultures (MSC+OEC+5%EPC or MSC+OEC+10%EPC). Co-cultures and
triple-cultures as indicated in the individual columns were analyzed for the endothelial
marker CD31 depicted in green (A, C) and myeloid marker CD11b depicted in red (A,B,C,D)
after 4 days (A,B) and 14 days (C,D). nuclei (blue), bar=100µm.
The effect of the addition of EPC was quantified by image analysis in cultures of at least three
different donors as depicted in figure 3. Representative overview pictures underlying the
quantification process are depicted for day 4 (figure 3.3 A) and for day 14 (figure 3.3 B). In
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comparison to the control group, represented by the co-culture of MSC and OEC, EPC added
in a ratio of 10% per total cells to the co-culture resulted in a significant increase in the area of
vascular structures (figure 3.3 C) at both investigated time points and with regard to the
skeleton of the vascular structures (figure 3.3 D) after 14 days of the culture process.
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Figure 3.3 Quantitative assessment of vascular structures influenced by the addition of EPC.
Co-cultures (MSC, OEC and MSC, EPC) and triple-cultures (MSC+OEC+5%EPC,
MSC+OEC+10%EPC) were stained for the endothelial marker CD31 after 4 days (A) and 14
days (B). The area (C) and the total skeleton length (D) of vascular structures formed by
co-cultures and triple-cultures after 4 days and 14 days were assessed quantitatively.
Statistical significance was defined as a P-value of less than 0.05 (*p < 0.05 and **p < 0.01)
n=9 samples. bar: 100µm.
3.3 Effects of myeloid cells on endothelial, myeloid and
vessel-stabilizing markers and genes
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To assess the effects exerted by myeloid cells added to the culture system in more detail, we
further evaluated endothelial markers such as vWF, CD31, CD146, as well as smooth muscle
actin involved in vascular stabilization and integrin-α5 by quantitative real time PCR (figure
3.4 A). Compared to the co-cultures of OEC and MSC used as reference group, the expression
of endothelial markers at day 4 was significantly higher in groups to which EPC were added
(figure 3.4 A), although the effects comparing 5% and 10% of EPC were not consistent. The
same trend was observed for smooth muscle actin associated with the vascular stabilization by
pericytes and integrin α-5 associated with angiogenic activation of endothelial cells.
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Figure 3.4 Expression of endothelial and myeloid markers. Relative expression of endothelial
or angiogenesis-related markers (A) and myeloid or macrophage-associated markers (B) in
co-cultures and triple-cultures was investigated by quantitative real-time PCR after 4 days
and 14 days. GAPDH was used as an endogenous standard to normalize the data and control
co-cultures were set to 1 (*p < 0.05 and **p < 0.01) n=3.
In addition, real time PCR was performed to analyse myeloid or macrophage-related markers
expressed by EPC or macrophage-like cells in the co-cultures. In these real time PCR
experiments the highest expression of CD11b as a marker of myeloid cells was observed in
the MSC/10% EPC co-cultures compared to the other groups, which confirms that EPC are
the main source of myeloid cells in our co-culture scenarios (figure 3.4 B). Similar findings
were observed for CD68 and CD163 used as macrophage markers for which we found
significantly higher expression rates in MSC/EPC co-cultures than in the OEC/pOB cultures.
3.4 Expression and secretion of IL-8 and VEGF
To assess the mechanisms responsible for the positive angiogenic effect by the EPC or
myeloid cell populations, we analysed the expression of IL-8 and VEGF by real time PCR, as
well as the corresponding concentrations of IL-8 and VEGF in cell cultures supernatants by
ELISA (figure 3.5). To cope with the different cell numbers in the co-culture set up, VEGF
and IL-8 concentrations were normalized to the DNA content. The highest levels of free IL-8
and VEGF were found in the MSC/ 10%EPC group (figure 3.5 B, D), whereas in the
co-cultures where mature endothelial cells were present, the concentration of free IL-8 and
VEGF were lower and showed no differences between the groups at day 4 of the culture. The
expression rates of VEGF and IL-8 after 14 days of cultures were slightly higher in the
MSC/OEC cultures to which we added the EPC. These results might indicate that EPC or
myeloid cells produce IL-8 and trigger the release of VEGF which is usually found in high
concentrations in osteogenic cell culture supernatants in accordance with our previous reports
44
[91, 92].
Figure 3.5 Relative quantification of gene expression of the proangiogenic factors IL-8 (A)
and VEGF (C) in co-cultures and triple-cultures after 4 days and 14 days. GAPDH was used
as an endogenous standard to normalize the data and control co-cultures were set to 1 (*p <
0.05 and **p < 0.01) n=3. (B, D) Release of proangiogenic factors in co-cultures and
triple-cultures. The concentration of IL-8 (B) and VEGF (D) in the supernatants of
co-cultures and triple-cultures after 4 days and 14 days was measured using an
enzyme-linked-immunosorbent-assay. Results were normalized to the DNA content of each
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sample to compensate for the different cell numbers in the set up (*p < 0.05 and **p < 0.01)
n=3.
3.5 Protein arrays for angiogenesis- and hematopoiesis-related
proteins
To assess the production of factors guiding angiogenesis in individual cell types and the
effects of the co-cultures on these molecules, we performed protein arrays for angiogenesis-
and hematopoiesis-related factors. Protein extracts were harvested from cell culture
supernatants and cell lysates to analyse soluble and membrane- or matrix-bound fractions of
the proteins. For this purpose proteins from the different fractions and culture approaches
were pooled in equal ratios from three independent experiments and thus are depicted as mean
values. In figure 3.6 A and figure 3.6 B results are depicted for VEGF, IL-8 and MCP-1 in cell
culture supernatants (A) and cell lysates (B). Amongst the groups we assessed, MSC as
monocultures were identified as the main producer of VEGF. In the co-cultures the levels of
free VEGF are reduced in comparison to MSC monocultures. Moreover, the addition of EPC
to the co-cultures of MSC and OEC further reduced the levels of free VEGF, whereas the
cell-bound fraction of VEGF in the triple culture of MSC, OEC and EPC, was slightly higher.
The highest IL-8 values in the supernatant were found in those of the co-cultures of OEC and
MSC, whereas the highest levels for IL-8 in the cell lysates were found in OEC monocultures.
In addition, in OEC lysates MCP-1 (monocyte-chemoattractant protein-1) was enriched, thus
favoring the idea that they are the main producer of MCP-1 within the investigated cell types.
In comparison, analysis of MCP-1 in the lysates indicates that the addition of EPC or myeloid
cells reduces the levels of free MCP-1.
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Figure 3.6 Human Proteome Profiler Array for Angiogenesis and Hematopoiesis.
Quantitative read-out of protein arrays for VEGF, IL-8, MCP-l in the cell culture
supernatants (A) and cell lysates (B) in mono-, co- and triple cultures. Key molecules which
drive angiogenesis found in the cell culture lysates (C,D). Results were depicted as mean pixel
densities resulting from protein profiler experiments by pooling the protein extracts in equal
ratios from 3 different donors.
By the protein arrays from cell lysates (figure 3.6 C,D) we identified several molecules which
were upregulated in co- and triple-cultures containing angiogenic structures, compared to
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MSC or OEC monocultures, in which no angiogenic structures were observed. These
molecules include coagulation factor III (also known as tissue factor), endoglin, pentraxin 3,
PD-ECGF and integrin-α 5. Furthermore, protein lysates of OEC showed high levels of
macrophage mannose receptor (MMR).
3.6 The formation angiogenic structures and the associated myeloid
cells grown on PU-HA scaffolds
We further explored the role of the CD11b-positive or myeloid cells were added to the
co-culture systems which were grown on PU-HA scaffolds. The formation of angiogenic
structures after 4 (figure 3.7 A, C) and 14 days (figure 3.7 B, D) was investigated by
immunofluoresecent staining for endothelial marker such as CD31 (depicted in green, figure
3.7) and for myeloid cells marker such as CD11b (depicted in red, figure 3.7) by CLSM. This
was performed either as overlays from 3-D projection to cope with the surface topography or
performed on sections derived from the scaffolds. In addition, the formation of angiogenic
structures was also observed by light microscopy after immunohistological staining for the
endothelial marker such as CD31 depicted in red (figure 3.8), which also enables to observe
the porous structure of the scaffolding material. During the time course of the co-cultures
OEC formed angiogenic structures characterized by elongated endothelial morphology on
scaffolds. Nevertheless, in further studies methods have to be developed which would allow
to quantify the effect of EPC or myeloid cells on the angiogenic structures in such a 3-D
model.
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Figure 3.7 Immunofluorescent staining of co-cultures (MSC+10%EPC, MSC+OEC) or
triple-cultures (MSC+OEC+5%EPC or MSC+OEC+10%EPC) on PU-HA scaffolds.
Co-cultures and triple-cultures as indicated in the individual columns were analyzed for the
endothelial marker CD31 depicted in green and myeloid marker CD11b depicted in red after
4 days (A, C) and 14 days (B, D). 3D pictures of PU-HA scaffolds (A, B) and the sections of
PU-HA scaffolds (C,D). nuclei (blue), bar=100µm.
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Figure 3.8 Immunohistological staining of co-cultures (MSC+OEC) or triple-cultures
(MSC+OEC+10%EPC) on PU-HA scaffolds. Angiogenic structures (arrows) could be
observed by light microscope. The sections of co-culture and triple-culture as indicated in the
individual columns were analyzed for the endothelial marker CD31 depicted in red after 14
days.
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4. Discussion
The interaction of resident endothelial cells, bone-forming cells and circulating endothelial
progenitor cells is crucial for bone tissue repair and the formation of new and functional
microvessels [93]. In this context it has been shown by previous data from co-culture
experiments of OEC and MSC that endogenous myeloid cells are co-localized with
angiogenic structures, thus implicating an important role during vascularization. Those data
are part of the doctorial thesis by Gerhard Kramer (Johannes Gutenberg University, Mainz)
and are also part of the manuscript by Yang Shi et al. (submitted). We hypothesized that those
myeloid cells derived from EPC which are still contained as residues in OEC cultures. As a
consequence in this present thesis early endothelial progenitor cells added to the co-cultures
of MSC and blood-derived endothelial cells (OEC) significantly improved the formation of
prevascular structures. Using several methods we have shown that early EPC act as myeloid
cells and can be identified as CD11b-positive cells. The addition of myeloid cells supports the
angiogenic process in different ways. This includes a beneficial effect on endothelial cell
growth, as indicated by a significant increase in endothelial markers in real time PCR. In
addition, EPC or myeloid cells produce angiogenic factors such as IL-8. The recruitment of
myeloid cells seems to be mediated by MCP-1 expressed by OEC. Further results indicate
that these myeloid cells act as M2 macrophages in co-cultures with MSC and OEC. Thus, the
addition of myeloid cells or EPC to complex tissue constructs might help to support the tissue
repair and neovascularization in the bone mediated by their macrophage-like properties.
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4.1 The effect of co-culture system on the endothelial phenotype and
angiogenic potential of outgrowth endothelial cells
It was previously shown that outgrowth endothelial cells from the peripheral blood can
support the formation of vascular structures in vitro and in vivo [92, 94] and might support or
accelerate blood perfusion during bone repair and in bone tissue engineered constructs. OEC
form cobblestone-like colonies and express markers of mature endothelial cells. They also
show a high proliferation and mature vessel-like structures under proangiogenic stimulation
[60]. The results of this thesis clearly show that co-culturing of MSC and OEC influences the
expression of CD146, CD31, and vWF in real time PCR as well as the formation of mature
vessel-like structures in vitro as indicated by confocal microscopy and immunofluorescence
staining for the endothelial marker CD31. In contrast there were no microvessel-like
structures in co-cultures of MSC and EPC at the investigated time point in this study.
Interaction between endothelial cells and osteogenic cells may be beneficial for bone repair
process [95]. Endothelial cells produce growth factors such as bone morphogenic protein-2
and Endothelin-1 which effect osteoprogenitor cells differentiation and proliferation [96, 97].
In the co-culture system outgrowth endothelial cells might also support the bone repair in
general by improving the vascularization and by the direct effects of endothelial cells on bone
forming cells.
4.2 Effects of myeloid cells on neovascularization
In reports from the literature it has also been shown that myeloid cells from the host which are
recruited to the sites of tissue repair or to implanted tissue constructs are also essential for the
neovascularization process [93]. This is in accordance with a series of reports identifying
myeloid cells as important mediators of neovascularization [98-100]. For example, CD11b+
cells produce high levels of MMP9 which is an important mediator in angiogenesis and plays
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a critical role in vascular stability [101, 102]. However, the relative contribution of myeloid
cells to vascular remolding is still unknown.
In co-cultures of OEC with osteogenic cells the staining for the myeloid marker CD11b also
indicated a co-localization of myeloid cells with angiogenic structures (Yang and Kramer et.
al, submitted). In these experiments myeloid cells are characterized by their rounded
morphology and also partially exhibited the expression of endothelial markers such as CD31.
These characteristics are also attributes of endothelial progenitor cells. Myeloid cells are
tentatively found at the tips or the nodes of the angiogenic network, which is in accordance
with previous reports in the literature about the role of myeloid cells or macrophages-like
cells in angiogenesis [103-105].
In this context the active addition of EPC or myeloid cells, respectively, improved the
formation of vascular structures significantly. CD31 (PECAM-1) is a cell adhesion molecule
(CAM) and has an important role in a number of endothelial cell functions including
angiogenesis, integrin activation and cell-cell adhesion [106]. The endothelial marker CD31
was used to distinguish endothelial cells from other cells in co-culture system. The co-culture
approach had three different set-ups 1) EPC were co-cultured with MSC 2) MSC were
co-cultured with OEC 3) EPC were co-cultured with MSC and OEC. Comparison of different
types of the co-cultures after 4 days and 14 days, showed that EPC contained cells which
were able to support the formation of primitive capillary-like structures in co-cultures of MSC
and OEC (Figure 3.3). In this context we evaluated a series of different markers involved in
blood vessel formation. In order to specify the effects of myeloid cells in the cultures we
compared the expression of endothelial markers such as vWF, CD31 and CD146, as well
smooth muscle actin as an indicator for vessel stabilization by smooth muscle cells and
integrin-α5 for angiogenic activation in quantitative real time PCR. vWF (von Willebrand
factor) is a glycoprotein that is synthesized in endothelial cells and essential for maintaining
the normal circulation of blood after tissue injury [107]. CD146 is a cell surface molecule and
is expressed in human endothelial cells as a component of the endothelial junctions [108].
After new blood vessels are being formed the blood vessels are stabilized by the association
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with smooth muscle cells. It is believed that endothelial cells can induce the differentiation of
mesenchymal cells into smooth muscle cells or pericytes [109]. Integrin-α5 is a receptor for
the extracellular matrix protein fibronectin and plays a critical role in angiogenesis [110]. On
the other hand Integrin-α5 is required for osteoblast differentiation of adult human
mesenchymal stromal cells and promotes the osteogenic capacity of human mesenchymal
stromal cells [111].
The increase in these markers in the groups to which we have added EPC was consistent
through the evaluated endothelial markers and was statistically significant at day 4. In the
group of MSC with 10% EPC the expression of endothelial markers was much lower in
accordance with no obvious presence of mature endothelial cells at the investigated time
point.
The mechanisms by which the EPC exert beneficial effects on endothelial cell growth could
be multifactorial and might also include the transdifferentiation of subpopulations of EPC into
mature endothelial cells [112]. Transdifferentiation of EPC to OEC might also occur in our
experimental settings, but could not be proven at the present state. On the other hand,
beneficial effects of EPC or myeloid cells on mature endothelial cells might be mediated by
paracrine effects.
4.3 Interaction between EPC/myeloid cells and other cells by paracrine
factors
Vascular endothelial growth factor (VEGF) is an essential regulator of physiological blood
vessel growth as described already in more detail in the introduction. Besides this important
role in the direct effect of VEGF in angiogenesis VEGF is essential to increase the generation
of immature myeloid cells and to promote monocyte migration [114] as well as to enhance
colony formation by granulocyte-macrophage progenitor cells [115]. Some groups have
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suggested VEGF as a factor which is responsible for the proangiogenic effects of EPC or
myeloid cells [56]. In addition, VEGF has been reported to recruit CD11b/Gr-1 and CXCR4
positive neutrophils supporting angiogenesis in mouse models [116]. In many reports from the
literature, MSC were confirmed as the main producer of VEGF as it was also shown in the
present study (figure 3.5). By comparing ELISA data, as well as VEGF levels by protein
arrays, lower VEGF levels in supernatants and higher levels in cell lysates, reflecting the
membrane- or matrix-bound fraction, characterized the triple cultures of OEC, MSC and EPC.
This is in accordance with previous results investigating the ratios of VEGF in co-culture
approaches. These previous studies also indicated low levels of VEGF in the supernatant but
higher fractions of membrane- or cell-bound levels of VEGF in cultures with high angiogenic
activity [91, 117]. ELISA data and data from the protein array gave slightly different results
but this might be associated with differences in the protein harvesting procedure for the arrays
or with the normalization of ELISA data to the cell number.
Another factor which has been proposed to mediate positive effects of myeloid cells on
angiogenesis is IL-8 [118] triggering endothelial proliferation and angiogenesis [119, 120].
Interleukin-8 is a chemokine that was recognized as a mediator of permeability and
angiogenesis . Transactivation of vascular endothelial growth factor receptor-2 by IL-8 is an
important signaling pathway and leads to the increase of angiogenesis [122]. In this studies
IL-8 appears to be derived from the early EPC or from mature endothelial cells. Angiogenic
activation in the co-cultures of OEC and MSC leads to high levels of IL-8 in the supernatant
which, in turn, are lowered by the addition of EPC to the system and a further improvement of
angiogenesis. We therefore assume that this is associated with the role of IL-8 to recruit
myeloid cells or endothelial progenitor cells to sites of vascular reorganization.
In addition, another molecule involved in the recruitment of EPC is MCP-1 produced by the
OEC, which showed the highest rates of MCP-1 in the cell lysates. The addition of EPC leads
to lower amounts of MCP-1 in the supernatants compared to the co-cultures of OEC and MSC.
This seems to be in accordance with a monocyte- or macrophage-like phenotype of EPC and
the role MCP-1 produced by late outgrowth endothelial cells [123] as an important regulator
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of angiogenesis. MCP is closely associated with N-Cadherin [124] and induced by
angiopoietin-1, leading to the recruitment of mural cells and the stabilization of angiogenic
structures [125]. MCP-1 was found to be upregulated in perivascular smooth muscle cells in
specimens of proliferative hemangioma but MCP-1 was not expressed in involuting
hemangiomas [126]. MCP-1 is a direct mediator of angiogenesis that is able to induce
endothelial cell migration and effects angiogenesis [127]. The upregulated expression of
VEGF-A can be induced by MCP-1 and the subsequent angiogenesis is then induced by
VEGF-A [128]. Therefore, the addition of EPC and the resulting lower MCP-1 values seem to
favor a proangiogenic state of the endothelial cells.
In addition, we observed effects on several molecules involved in vascular control. Some of
these molecules were much more abundant in cell lysates of co-cultures in which angiogenic
structures were present than in the corresponding mono-cultures which are free of angiogenic
structures. Moreover, these molecules were affected by the addition of early EPC or myeloid
cells. These factors include coagulation factor III also known as tissue factor, endoglin,
pentraxin 3, PD-ECGF and integrin-α 5. Tissue factor is also involved in the formation of
complex and stable microvessels characterized by the stabilization of vascular structures
through mesenchymal cells [129], which is mediated by the regulation of MCP-1 as described
before in the literature [130] and in accordance with our observations for MCP-1, as described
above. Pentraxin-3 is a negative regulator of angiogenesis due to its binding to the
proangiogenic molecule fibroblast growth factor-2 [131], which is an important factor in the
cellular cross talk of endothelial cells, pericytes and stromal cells. It has been shown that
pentraxin-3 inhibits endothelial cell proliferation and migration [132]. Thus, the addition of
EPC or myeloid cells to the system lowers the pentraxin-3 levels and contributes to the
proangiogenic activity of the endothelial cells. Platelet-derived endothelial cell growth factor
(PD-ECGF) is an angiogenic factor initially isolated from platelets [133] and has been
detected in macrophages, stromal cells, and some epithelia [134]. Endoglin plays a
multifaceted role in vascular biology and is expressed in endothelial cells in inflamed tissues.
As recently shown, endoglin is involved in leucocyte adhesion and transmigration in the
vascular system via the integrin α5ß1 receptor of leukocytes [135].
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4.4 Association of macrophage with angiogenesis
Surprisingly high levels of macrophage mannose receptor (MMR) were found in the cell
lysates of OEC. Although there are also reports from the literature that this marker is
associated with endothelial cells [136, 137], MMR is widely accepted as a M2 macrophage
marker [118, 138, 139]. Further experiments are currently underway to evaluate these findings
by additional methods. Real time PCR experiments indicated that EPC contain
macrophage-like cells expressing high ratios of CD11b and CD68. In co-culture with MSC
they might differentiate towards cells with characteristics of M2 macrophages, as indicated by
the expression of CD163 in the MSC/EPC cultures. Recently, emerging evidence has been
provided that M1 macrophages in co-culture with endothelial cells [140] or mesenchymal
stem cells [138, 141, 142] assume a M2-like phenotype which is responsible for
anti-inflammatory and proangiogenic effects in tissue repair. In this context, the role of EPC
or myeloid cells in neovascularization might be explained by their function as
macrophage-like cells. Further experiments are underway to further define macrophage-like
properties of EPC in the context of bone repair and neovascularization in vitro and in vivo.
4.5 Co-culture systems on PU-HA scaffolds for bone tissue engineering
Tissue engineering scaffolds should act as temporary ECM substitutes and are able to support
cell and ECM interactions such as adhesion, differentiation and migration . A successful
scaffold for bone repair should promote osteogenesis and the development of vascular
networks in order to create a functional bone tissue. For example, mesenchymal stem cells
can be seeded onto scaffolds and differentiated into chondrogenic and osteogenic cells [144].
In addition it has been shown previously that microvessel-like structures can be generated
from outgrowth endothelial cells (OEC) within a scaffold by angiogenic stimuli such as the
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co-culture process with osteogenic cells [86]. Thus we further explored the before mentioned
the co-culture systems including also EPC or myeloid cells based on PU-HA as scaffolding
materials with the aim to develop a construct which ensures endothelial and osteogenic
functions.
We observed micro-vascular networks within Polyurethane-Hydroxyapatite (PU-HA)
scaffolds after immunofluorescent staining and confocal laser scanning microscopy.
Prevascular structures were induced by co-culturing of OEC with MSC on PU-HA scaffolds
whereas no structures were observed in co-cultures of EPC with MSC on PU-HA scaffolds.
Then, co-culture of OEC and MSC on PU-HA scaffolds plus the addition of EPC showed the
contribution of EPC to vascular structures investigated after 4 days and 14 days. In general,
the vascular structures on the scaffold increased during the culture process but an effect of the
EPC on the formation of vascular structures, as well as this increase over time have to be
quantified and investigated in detail in the future. Nevertheless, quantification of angiogenic
structures showed the proangiogenic effect of EPC under 2-D conditions as reported in
previous sections. Furthermore, an increase in vascular structures over time was already
shown before in similar experiments on other types of scaffolding materials [90]. In this
experimental study the growing and the maturation of the vascular network at later culture
time were observed by CLSM (figure 3.7) and in immunohistochemistry of sections from the
scaffolds. The endothelial cells and vascular structures staining for CD31 indicate that EPC
might promote the vascular structure in triple-culture system (figure 3.8) on the scaffolds. The
more vascular networks penetrate though the pores of scaffolds in the triple-cultures and reach
also the inner parts of the construct (MSC+OEC+10%EPC), the better and faster the
vascularization might proceed after the implantation. Here, in vivo studies would have to be
performed in order to see whether this effect will be consistent in an in vivo situation.
4.6 Conclusions
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Angiogenesis plays an important role in the bone repair. Endothelial progenitor cells can be
isolated from the peripheral blood and expanded under specific culture conditions. In addition
although endothelial progenitor cells are a heterogeneous population of cells some endothelial
progenitor cells are able to give rise to outgrowth endothelial cells that have a high
proliferative and vasculogenic potential. Investigation of cellular and molecular processes
guiding angiogenesis may enhance our understanding of new blood formation and offer the
opportunity to stimulate angiogenesis during tissue repair by suitable signaling molecules.
The present study showed that the vasculogenic potential of OEC in co-culture with MSC for
bone tissue engineering applications including the angiogenic activation and vessel
stabilization. The angiogenic molecules such as VEGF effect the vessel growth in the
co-culture system and then in a secondary effect enhance bone fracture repair and
regeneration. In addition, the present study gives an insight into the pro-angiogenic action of
myeloid cells or endothelial progenitor cells that seems to support the formation of
microvessel-like structures. The effects of myeloid cells seem to be mediated by factors of
such as IL-8, MCP-1, coagulation factor III, endoglin, pentraxin 3, PD-ECGF and integrin-α 5.
Furthermore the data provide evidence that mixed application of mature endothelial cells,
MSCs and endothelial progenitor cells can support the neovascularization process. Coating of
Polyurethane biomaterials with Hydroxyapatite (PU-HA) combine a widely used and
characterized biomaterial with the biomimetic surface of a bone substitute material. In this
study PU-HA scaffolds have been shown to support the formation of a vascularized tissue
with organized vascular structures. Further studies will have to reveal if the additional
application of EPC leads to an improved vascularization of such constructs in vivo. For this
purpose the growth of the cells types on this type of an artificial bone matrix and the
formation of a complex vascular structure serves as an initial step towards an artificial bone
construct on a 3-D matrix. In addition we are currently also evaluating potential effects of the
triple culture of OEC, EPC and MSC on the osteogenic differentiation.
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5. Summary
Repair of large skeletal defects is still a major clinical challenge in orthopaedic and
reconstructive surgery. Currently investigated bone tissue engineering strategies might offer
new opportunities to regenerate these defects. Bone is a well-vascularized tissue which
requires an effective blood supply by nutrient artery, periosteal vessels, and epiphyseal vessels
[145]. Thus a better understanding of the mechanisms and contributing cell types in blood
vessel organization during bone repair might also support the bone regeneration in general. In
this context the interaction of MSC and endothelial cells plays an essential role during blood
vessel organization in vivo and can be partly mimicked in co-culture systems of endothelial
cells and osteogenic cells. Recent studies have shown that myeloid cells significantly
contribute to the neovascularization of the bone. Thus the present study was carried out to
evaluate the role of EPC as a potential source of myeloid cells in the formation of vascular
structures in a co-culture model consisting of mesenchymal stem cells (MSC) and outgrowth
endothelial cells (OEC). The molecular effects of myeloid cells or EPC respectively were
evaluated by quantitative real time PCR, ELISA, and protein arrays from cell culture
supernatants and lysates. The active addition of EPC to co-cultures of MSC and OEC resulted
in a significant increase in the formation of prevascular structures at early stages of the
co-culture process. In addition, a significant increase of endothelial markers was observed
indicating a beneficial effect of myeloid cells on endothelial cell growth. Furthermore, the
high expression levels of CD11b and CD163 by real time PCR in co-cultures of EPC and
MSC indicated that EPC act at least partly as macrophage like-cells. In initial studies this
approach was then transferred to a biomaterial application based on polyurethane scaffolds
coated with hydroxyapatite. First results indicate the formation of prevascular structures on
this type of 3-D matrix and thus can serve as a basis for in vivo studies in following
experiments. The relevant subpopulations with pro-angiogenic activity in EPC or myeloid
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cells and their detailed function enhancing the vascularization process are currently defined in
ongoing experiments.
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